A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.

The article describes an experimental recombinant vaccine that was developed to protect horses from West Nile virus, highlighting its initial success in stimulating anti-viral immune responses.

Introduction and Purpose

• The authors acknowledge the endemic nature of the West Nile Virus (WNV) in the U.S. and its severe effects on horses, leading to neurologic disease.
• The research is motivated by the lack of effective pharmaceutical treatments for the WNV infection, hence the reliance on vaccination as the main method of prevention and management of the disease.
• The purpose of the study was to assess the efficacy of a recombinant vaccine that combines domain III (DIII) of the WNV envelope glycoprotein with, and without, a natural adjuvant equine CD40 ligand (CD40L).

Results: Antibody Production and Viral Neutralization

• The primary metric of the study was the production of virus-neutralizing antibodies in the horses. This was measured by observing serum IgG1 concentrations.
• The results indicated a significant increase (p<0.05) in these IgG1 concentrations in horses that were vaccinated with the DIII-CD40L + TiterMax and DIII-CD40L proteins, compared to other groups.
• However, the concentration of other antibodies (IgG4, IgG7, IgG3, IgG5) did not significantly increase among all groups.
• The Western blot results (a method for detecting specific protein molecules from among a mixture of proteins) showed that the highest specific anti-DIII antibody activities occurred in animals immunized with the DIII-CD40L protein, with or without TiterMax, after the vaccination.
• Importantly, stronger neutralizing activity (p<0.05) compared to other groups was observed in animals immunized with the DIII-CD40L protein (with or without TiterMax) starting at week eight.

Results: Cellular Immune Response

• The vaccine was able to stimulate more CD8T cells but not CD4T cells in equine peripheral blood mononuclear cells (PMBCs). CD8T cells are important for the body’s immune response, being instrumental in killing cells infected with pathogens.
• Hence, the recombinant WNV E DIII-CD40L protein stimulated both humoral (antibody-mediated) and cellular immune responses in healthy horses.

Conclusion

• The research findings suggest that the DIII-CD40L protein could potentially protect against WNV-associated disease in infected animals.
• Moreover, CD40L could serve as a non-toxic, alternative adjuvant to enhance the immunogenicity (ability to provoke an immune response) of subunit vaccines in horses.